Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Melanie Joy to Renal Dialysis

This is a "connection" page, showing publications Melanie Joy has written about Renal Dialysis.

 
Connection Strength
 
 
 
0.885
 
  1. Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Ann Pharmacother. 2008 Jan; 42(1):9-15.
    View in: PubMed
    Score: 0.278
  2. Joy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis. 1998 Jun; 31(6):1019-27.
    View in: PubMed
    Score: 0.144
  3. Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm. 1995 Sep 01; 52(17):1895-900.
    View in: PubMed
    Score: 0.119
  4. Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin. 2005 May; 21(5):657-64.
    View in: PubMed
    Score: 0.058
  5. Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004 Sep; 62(3):193-201.
    View in: PubMed
    Score: 0.056
  6. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003 Jul; 42(1):96-107.
    View in: PubMed
    Score: 0.051
  7. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002 Feb; 39(2):297-307.
    View in: PubMed
    Score: 0.047
  8. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2000 Jun; 44(6):1639-44.
    View in: PubMed
    Score: 0.041
  9. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy. 2000 Jun; 20(6):635-43.
    View in: PubMed
    Score: 0.041
  10. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998 Mar; 32(3):362-75.
    View in: PubMed
    Score: 0.035
  11. Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy. 2005 Mar; 25(3):335-44.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)